At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LINE Lineage
Closed 05-06 16:00:00 EDT
37.81
+1.31
+3.59%
盘后37.81
+0.000.00%
18:13 EDT
High38.68Low35.67Vol1.52M
Open35.88D1 Closing36.50Amplitude8.26%
Mkt Cap8.59BTradable Cap2.18BTotal Shares227.08M
T/O56.80MT/O Rate2.63%Tradable Shares57.64M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Lineage, Inc. Earnings Call Balances Progress And Risk
TIPRANKS  ·  09:15
Lineage, Inc. Earnings Call Balances Progress And Risk
Lineage Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-06 21:32
Lineage Inc reports results for the quarter ended March 31 - Earnings Summary
Lineage Posts Modest Growth and Raises Dividend Outlook
TIPRANKS  ·  05-06 19:36
Lineage Posts Modest Growth and Raises Dividend Outlook
Adam Kramer Maintains Hold on Lineage Amid Transitional 2026, Soft Same-Store Trends, and Uncertain Demand Recovery
TIPRANKS  ·  05-06 18:28
Adam Kramer Maintains Hold on Lineage Amid Transitional 2026, Soft Same-Store Trends, and Uncertain Demand Recovery
Lineage Q1 Adjusted FFO Falls, Revenue Rises; Reiterates Full-Year AFFO Outlook
MT Newswires Live  ·  05-06 18:22
Lineage Q1 Adjusted FFO Falls, Revenue Rises; Reiterates Full-Year AFFO Outlook
GUIDANCE: (LINE) Lineage Expects 2026 Adjusted FFO per Share Range $2.75 to $3.00, vs. FactSet Est of $2.88
MT Newswires Live  ·  05-06 18:19
GUIDANCE: (LINE) Lineage Expects 2026 Adjusted FFO per Share Range $2.75 to $3.00, vs. FactSet Est of $2.88
Lineage Q1 revenue misses estimates, adjusted EBITDA beats
Reuters  ·  05-06 18:14
Lineage Q1 revenue misses estimates, adjusted EBITDA beats
Earnings Flash (LINE) Lineage Posts Q1 AFFO $0.78 a Share, vs. FactSet Est of $0.70
MT Newswires Live  ·  05-06 18:08
Earnings Flash (LINE) Lineage Posts Q1 AFFO $0.78 a Share, vs. FactSet Est of $0.70
Lineage Q1 EPS $(0.18) Misses $(0.14) Estimate, Sales $1.297B Miss $1.322B Estimate
Benzinga  ·  05-06 18:03
Lineage Q1 EPS $(0.18) Misses $(0.14) Estimate, Sales $1.297B Miss $1.322B Estimate
Lineage Inc - Sees FY2026 Adj Ebitda $1.25-$1.30 Bln; Affo per Share $2.75-$3.00
THOMSON REUTERS  ·  05-06 18:00
Lineage Inc - Sees FY2026 Adj Ebitda $1.25-$1.30 Bln; Affo per Share $2.75-$3.00
Lineage Inc: Supply Chain Conditions Remain Challenging Due to Tariff Uncertainty and Geopolitical Disruptions
THOMSON REUTERS  ·  05-06 18:00
Lineage Inc: Supply Chain Conditions Remain Challenging Due to Tariff Uncertainty and Geopolitical Disruptions
Lineage Inc Q1 Adjusted Ffo per Share USD 0.78
THOMSON REUTERS  ·  05-06 18:00
Lineage Inc Q1 Adjusted Ffo per Share USD 0.78
Lineage Inc Q1 Pretax Profit USD -47 Million
THOMSON REUTERS  ·  05-06 18:00
Lineage Inc Q1 Pretax Profit USD -47 Million
Lineage, Inc. Reports First-Quarter 2026 Financial Results
THOMSON REUTERS  ·  05-06 18:00
Lineage, Inc. Reports First-Quarter 2026 Financial Results
Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside
Dow Jones  ·  05-06 04:34
Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside
Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  05-04 21:39
Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital
Lineage Inc expected to post a loss of 6 cents a share - Earnings Preview
Reuters  ·  05-04 20:59
Lineage Inc expected to post a loss of 6 cents a share - Earnings Preview
Earning Preview: Lineage this quarter’s revenue is expected to decrease by 1.25%, and institutional views are leaning bullish
Earnings Agent  ·  04-29
Earning Preview: Lineage this quarter’s revenue is expected to decrease by 1.25%, and institutional views are leaning bullish
Lineage Cell Therapeutics Initiated at Buy by Canaccord Genuity
Dow Jones  ·  04-29
Lineage Cell Therapeutics Initiated at Buy by Canaccord Genuity
Canaccord Genuity Initiates Coverage on Lineage Cell Therapeutics With Buy Rating, $9 PT
MT Newswires Live  ·  04-28
Canaccord Genuity Initiates Coverage on Lineage Cell Therapeutics With Buy Rating, $9 PT

Introduction

Company Name.
Lineage
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--